The tumor lysis syndrome.
作者信息
Howard Scott C, Jones Deborah P, Pui Ching-Hon
机构信息
Department of Oncology and International Outreach Program, St. Jude Children's Research Hospital, Memphis, TN 38105-2794, USA.
出版信息
N Engl J Med. 2011 May 12;364(19):1844-54. doi: 10.1056/NEJMra0904569.
Abstract
摘要
相似文献
1
The tumor lysis syndrome.肿瘤溶解综合征
N Engl J Med. 2011 May 12;364(19):1844-54. doi: 10.1056/NEJMra0904569.
2
Tumor lysis syndrome and acute renal failure--an increasing spectrum of presentations.肿瘤溶解综合征与急性肾衰竭——临床表现谱不断扩大
Clin Nephrol. 2007 Sep;68(3):186-9. doi: 10.5414/cnp68186.
3
Tumor lysis syndrome: pathogenesis and management.肿瘤溶解综合征：发病机制与管理
Pediatr Nephrol. 1995 Apr;9(2):206-12. doi: 10.1007/BF00860751.
4
Tumour lysis syndrome.肿瘤溶解综合征。
Med Clin (Barc). 2019 May 17;152(10):397-404. doi: 10.1016/j.medcli.2018.10.029. Epub 2019 Jan 3.
5
Managing tumor lysis syndrome in 2010.2010年肿瘤溶解综合征的管理
Leuk Lymphoma. 2010 Feb;51(2):179-80. doi: 10.3109/10428190903488788.
6
Rasburicase for Tumor Lysis Syndrome.重组尿酸氧化酶治疗肿瘤溶解综合征
Am J Ther. 2019 Jan/Feb;26(1):e118-e121. doi: 10.1097/MJT.0000000000000462.
7
[Tumor lysis syndrome].[肿瘤溶解综合征]
Nihon Rinsho. 2012 Aug;70 Suppl 6:423-7.
8
Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management.肿瘤溶解综合征和急性肾损伤：评估、预防和管理。
Am J Kidney Dis. 2010 May;55(5 Suppl 3):S1-13; quiz S14-9. doi: 10.1053/j.ajkd.2009.10.056.
9
[Acute renal failure in patients with tumor lysis syndrome].[肿瘤溶解综合征患者的急性肾衰竭]
Nihon Rinsho. 2004 May;62 Suppl 5:486-90.
10
[Acute kidney injury secondary to steroid-induced tumor lysis in an adolescent with acute lymphoblastic leukemia: role of urinary alkalinisation and peritoneal dialysis].[急性淋巴细胞白血病青少年患者中类固醇诱导肿瘤溶解继发的急性肾损伤：尿碱化和腹膜透析的作用]
Arch Argent Pediatr. 2012 Dec;110(6):e118-22. doi: 10.5546/aap.2012.e118.
引用本文的文献
1
Characterizing the Real-World Risks of Kidney Injuries Associated with Chimeric Antigen Receptor T Cell Therapies-Evidence and Safety.评估嵌合抗原受体T细胞疗法相关肾损伤的真实世界风险——证据与安全性
Health Data Sci. 2025 Sep 2;5:0325. doi: 10.34133/hds.0325. eCollection 2025.
2
Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.维奈托克和伊布替尼治疗日本复发/难治性套细胞淋巴瘤患者的长期疗效
Int J Clin Oncol. 2025 Sep 2. doi: 10.1007/s10147-025-02865-4.
3
Real-World Safety and Efficacy of Venetoclax in Chronic Lymphocytic Leukemia: A Single-Center Comparative Analysis With Randomized Clinical Trials.维奈托克在慢性淋巴细胞白血病中的真实世界安全性和疗效：一项与随机临床试验的单中心比较分析
Adv Hematol. 2025 Aug 19;2025:3910332. doi: 10.1155/ah/3910332. eCollection 2025.
4
Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report.维奈克拉/卡非佐米/地塞米松治疗复发/难治性多发性骨髓瘤并发肿瘤溶解综合征：一例报告
Reports (MDPI). 2024 Nov 29;7(4):108. doi: 10.3390/reports7040108.
5
Management of acute kidney injury in tumor lysis syndrome: a narrative review.肿瘤溶解综合征中急性肾损伤的管理：一项叙述性综述。
Intern Emerg Med. 2025 Jul 19. doi: 10.1007/s11739-025-04050-x.
6
A Case of Spontaneous Tumor Lysis Syndrome With Acute Kidney Injury and the Timing of Chemotherapy.一例伴有急性肾损伤的自发性肿瘤溶解综合征及化疗时机
Cureus. 2025 Jun 4;17(6):e85342. doi: 10.7759/cureus.85342. eCollection 2025 Jun.
7
Taurine alleviates hyperuricemia-induced nephropathy in rats: insights from microbiome and metabolomics.牛磺酸减轻大鼠高尿酸血症诱导的肾病：来自微生物组学和代谢组学的见解
Front Nutr. 2025 Jun 18;12:1587198. doi: 10.3389/fnut.2025.1587198. eCollection 2025.
8
Immunotherapy-associated hemostatic abnormalities: bleeding and thrombotic complications.免疫治疗相关的止血异常：出血和血栓形成并发症。
Ann Hematol. 2025 Jul;104(7):3537-3551. doi: 10.1007/s00277-025-06482-z. Epub 2025 Jul 1.
9
Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma.嵌合抗原受体T细胞（CAR-T）疗法对复发难治性多发性骨髓瘤患者的肾毒性
Int Urol Nephrol. 2025 May 1. doi: 10.1007/s11255-025-04503-4.
10
Incidence of Tumour Lysis Syndrome in Patients with Acute Myeloid Leukemia During Initiation of Therapy with Azacitidine and Venetoclax: A Retrospective Chart Review from a Canadian Single-Centre Perspective.阿扎胞苷和维奈克拉起始治疗期间急性髓系白血病患者肿瘤溶解综合征的发生率：一项来自加拿大单中心视角的回顾性图表审查
Curr Oncol. 2025 Apr 2;32(4):213. doi: 10.3390/curroncol32040213.
本文引用的文献
1
Genetic disorders of renal phosphate transport.肾脏磷酸盐转运的遗传性疾病。
N Engl J Med. 2010 Jun 24;362(25):2399-409. doi: 10.1056/NEJMra0904186.
2
A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome.一名接受甲苯磺酸索拉非尼治疗的晚期肝细胞癌患者出现大量肿瘤溶解，且未发生肿瘤溶解综合征。
Intern Med. 2010;49(11):991-4. doi: 10.2169/internalmedicine.49.3153. Epub 2010 Jun 1.
3
Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management.肿瘤溶解综合征和急性肾损伤：评估、预防和管理。
Am J Kidney Dis. 2010 May;55(5 Suppl 3):S1-13; quiz S14-9. doi: 10.1053/j.ajkd.2009.10.056.
4
A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults.用于治疗成人肿瘤溶解综合征的单次固定剂量的拉布立酶（最大剂量6毫克）。
Eur J Haematol. 2010 Aug;85(2):177-9. doi: 10.1111/j.1600-0609.2010.01457.x. Epub 2010 Apr 12.
5
Oral phosphate binders in patients with kidney failure.肾衰竭患者的口服磷结合剂
N Engl J Med. 2010 Apr 8;362(14):1312-24. doi: 10.1056/NEJMra0912522.
6
Tumor lysis syndrome associated with carboplatin and paclitaxel in a woman with recurrent endometrial cancer.一名复发性子宫内膜癌女性患者中与卡铂和紫杉醇相关的肿瘤溶解综合征。
Int J Gynaecol Obstet. 2010 Jun;109(3):254. doi: 10.1016/j.ijgo.2010.02.005. Epub 2010 Apr 1.
7
Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.评估低剂量、基于体重的拉布立酶用于成年患者治疗或预防肿瘤溶解综合征的效果。
J Oncol Pharm Pract. 2011 Sep;17(3):147-54. doi: 10.1177/1078155210364180. Epub 2010 Mar 23.
8
Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.恶性肿瘤成人和儿童肿瘤溶解综合征（TLS）风险评估和预防推荐：专家 TLS 小组共识。
Br J Haematol. 2010 May;149(4):578-86. doi: 10.1111/j.1365-2141.2010.08143.x. Epub 2010 Mar 16.
9
Managing tumor lysis syndrome in 2010.2010年肿瘤溶解综合征的管理
Leuk Lymphoma. 2010 Feb;51(2):179-80. doi: 10.3109/10428190903488788.
10
Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.索拉非尼致晚期肝细胞癌肿瘤溶解综合征
World J Gastroenterol. 2009 Sep 21;15(35):4464-6. doi: 10.3748/wjg.15.4464.
Zotero 插件